InspireMD (NYSE:NSPR) Director Paul Stuka Acquires 20,000 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka acquired 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average cost of $0.88 per share, with a total value of $17,600.00. Following the acquisition, the director directly owned 667,871 shares of the company’s stock, valued at $587,726.48. This trade represents a 3.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka acquired 10,000 shares of InspireMD stock. The stock was purchased at an average cost of $1.19 per share, with a total value of $11,900.00.
• On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The stock was purchased at an average cost of $1.16 per share, with a total value of $76,126.16.
• On Thursday, May 7th, Paul Stuka acquired 6,378 shares of InspireMD stock. The stock was purchased at an average cost of $1.15 per share, with a total value of $7,334.70.
• On Wednesday, May 6th, Paul Stuka acquired 1,517 shares of InspireMD stock. The stock was purchased at an average cost of $1.12 per share, with a total value of $1,699.04.

InspireMD Trading Up 2.3%

Shares of NSPR opened at $0.92 on Friday. InspireMD, Inc. has a 12-month low of $0.86 and a 12-month high of $2.93. The firm has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.62. The firm has a market capitalization of $43.12 million, a P/E ratio of -1.23 and a beta of 0.82.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NSPR. Renaissance Technologies LLC acquired a new position in InspireMD in the first quarter valued at about $29,000. XTX Topco Ltd acquired a new position in InspireMD in the fourth quarter valued at about $30,000. Virtu Financial LLC acquired a new position in InspireMD in the fourth quarter valued at about $31,000. Creative Planning acquired a new position in InspireMD in the second quarter valued at about $44,000. Finally, Legato Capital Management LLC acquired a new position in InspireMD in the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

Analyst Ratings Changes

NSPR has been the subject of a number of analyst reports. Loop Capital set a $5.00 price objective on shares of InspireMD in a report on Tuesday, February 24th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Maxim Group initiated coverage on shares of InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Lake Street Capital set a $4.00 target price on shares of InspireMD in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InspireMD currently has an average rating of “Buy” and an average target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.